JAY M MOYES
CIK 1191062 · Chief Financial Officer · last filed 2026-07-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$822.8K
Companies
10
Total Filings
82
Lifetime Open-Market Net
-$7.20M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCDA | Director | — | $0.78 | — | $0 | 6 | 2026-07-07 |
| PBYI | Director | 58,322 | $7.97 | $464.8K | -$919.6K | 22 | 2026-06-15 |
| SINT | Director | 4,000 | $1.56 | $6.2K | $13.7K | 2 | 2026-02-25 |
| BioCardia, Inc. (BCDAW) Delisted | Director | 54,267 | $0.01 | $331 | $0 | 10 | 2023-10-19 |
| SERA | Chief Financial Officer | 35,630 | $2.03 | $72.3K | $0 | 3 | 2023-03-07 |
| ACHV | Director | — | $6.18 | — | $0 | 6 | 2022-06-01 |
| ACHIEVE LIFE SCIENCES, INC. (OGXI) Delisted | Director | — | — | — | $0 | 1 | 2017-08-03 |
| Sintx Technologies, Inc. (AMDA) Delisted | Chief Financial Officer | 66,562 | — | — | $0 | 1 | 2014-02-21 |
| OSIRIS THERAPEUTICS, INC. (OSIR) Delisted | Director | 26,500 | — | — | $0 | 8 | 2014-02-07 |
| MYGN | Chief Financial Officer | 52,512 | $5.32 | $279.4K | -$6.29M | 18 | 2007-10-16 |
Recent Filings · Page 3 of 9
82 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-01 | ACHV | Grant (A) | — | $0 | EDGAR |
| 2022-03-25 | SERA | Grant (A) | — | $0 | EDGAR |
| 2021-07-21 | SERA | Conv (C) | +2,830 | $0 | EDGAR |
| 2021-06-17 | PBYI | Grant (A) | +27,858 | $0 | EDGAR |
| 2021-06-15 | BioCardia, Inc. (BCDAW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-11 | PBYI | Sell (S) | −25,248 | -$286.9K | EDGAR |
| 2021-05-13 | ACHV | Grant (A) | — | $0 | EDGAR |
| 2021-04-07 | BioCardia, Inc. (BCDAW) Delisted | Grant (A) | +3,456 | $0 | EDGAR |
| 2021-01-05 | BioCardia, Inc. (BCDAW) Delisted | Grant (A) | +6,550 | $0 | EDGAR |
| 2020-10-09 | BioCardia, Inc. (BCDAW) Delisted | Grant (A) | +3,750 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.